NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis $6.43 +0.09 (+1.42%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$6.36 -0.07 (-1.17%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Coya Therapeutics Stock (NASDAQ:COYA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Coya Therapeutics alerts:Sign Up Key Stats Today's Range$6.25▼$6.5050-Day Range$5.32▼$6.7252-Week Range$4.65▼$10.24Volume20,205 shsAverage Volume84,128 shsMarket Capitalization$107.57 millionP/E RatioN/ADividend YieldN/APrice Target$16.50Consensus RatingBuy Company Overview Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. Read More Coya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreCOYA MarketRank™: Coya Therapeutics scored higher than 39% of companies evaluated by MarketBeat, and ranked 1382nd out of 1,841 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCoya Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCoya Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Coya Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.15) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -6.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coya Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.61% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Coya Therapeutics has recently decreased by 0.99%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.61% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Coya Therapeutics has recently decreased by 0.99%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News SentimentN/A News SentimentCoya Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Coya Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows3 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Coya Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 39.75% of the stock of Coya Therapeutics is held by institutions.Read more about Coya Therapeutics' insider trading history. Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address COYA Stock News HeadlinesCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral CapitalJuly 27, 2025 | americanbankingnews.comCoya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025July 22, 2025 | finance.yahoo.comTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative... | InvestorPlace (Ad)Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025July 22, 2025 | businesswire.comLake Street Initiates Coverage of Coya Therapeutics (COYA) with Buy RecommendationJuly 10, 2025 | msn.comCoya Therapeutics resubmits IND application for ALS Phase 2 study to FDA - Investing.comJuly 2, 2025 | investing.comPositive Outlook for Coya Therapeutics, Inc. Driven by IND Resubmission and Promising Trial ResultsJuly 1, 2025 | tipranks.comAfter myriad failures, a new wave of ALS drugs approachesJune 25, 2025 | finance.yahoo.comSee More Headlines COYA Stock Analysis - Frequently Asked Questions How have COYA shares performed this year? Coya Therapeutics' stock was trading at $5.73 at the beginning of the year. Since then, COYA shares have increased by 12.2% and is now trading at $6.43. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.44) EPS for the quarter, hitting the consensus estimate of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analyst estimates of $2.63 million. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share. Who are Coya Therapeutics' major shareholders? Top institutional shareholders of Coya Therapeutics include AIGH Capital Management LLC (6.61%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman. View institutional ownership trends. How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/13/2025Today8/05/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COYA CIK1835022 Webwww.coyatherapeutics.com Phone800-587-8170FaxN/AEmployees6Year FoundedN/APrice Target and Rating Average Price Target for Coya Therapeutics$16.50 High Price Target$18.00 Low Price Target$14.00 Potential Upside/Downside+156.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.88 million Net MarginsN/A Pretax Margin-484.56% Return on Equity-48.88% Return on Assets-43.32% Debt Debt-to-Equity RatioN/A Current Ratio8.84 Quick Ratio8.84 Sales & Book Value Annual Sales$3.55 million Price / Sales30.30 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book2.71Miscellaneous Outstanding Shares16,730,000Free Float14,718,000Market Cap$107.57 million OptionableNot Optionable Beta0.26 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:COYA) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.